
Quarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals Net Debt 2011-2025 | ZYNE
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.3 M | -67.2 M | - | -69.7 M | -59.8 M | -62.5 M | -31 M | -41.5 M | -9.33 M | 345 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 345 K | -69.7 M | -43.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
193 M | $ 1.2 | 0.42 % | $ 129 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
-1.07 B | $ 2.67 | 0.19 % | $ 1.39 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
285 M | $ 4.32 | -3.79 % | $ 86.3 M | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
-10.2 M | - | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | ||
|
Emergent BioSolutions
EBS
|
338 M | $ 12.28 | -1.17 % | $ 629 M | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | $ 21.57 | -0.12 % | $ 2.05 B | ||
|
Evolus
EOLS
|
36.3 M | $ 6.67 | -3.33 % | $ 414 M | ||
|
Harrow Health
HROW
|
173 M | $ 50.64 | 1.09 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
-4.73 M | $ 1.27 | -1.17 % | $ 22.2 M | ||
|
OrganiGram Holdings
OGI
|
90.7 M | $ 1.71 | -4.47 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
-131 M | $ 5.22 | -1.14 % | $ 687 M | ||
|
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | ||
|
Bausch Health Companies
BHC
|
21.1 B | $ 7.15 | -0.69 % | $ 2.61 B | ||
|
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 3.66 | 1.25 % | $ 4.54 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 4.02 | -2.31 % | $ 56.5 M | ||
|
Rockwell Medical
RMTI
|
691 K | $ 0.82 | -5.16 % | $ 19.1 M | ||
|
Pacira BioSciences
PCRX
|
317 M | $ 26.19 | -1.21 % | $ 1.21 B | ||
|
Sundial Growers
SNDL
|
-28.4 M | $ 1.73 | -0.29 % | $ 3.37 M | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
Veru
VERU
|
-20.9 M | $ 2.2 | -8.33 % | $ 297 M | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
3.05 B | $ 13.87 | 0.4 % | $ 1.91 B | ||
|
ProPhase Labs
PRPH
|
-6.41 M | $ 0.45 | -13.46 % | $ 7.13 M | ||
|
cbdMD
YCBD
|
-521 K | $ 1.46 | -14.41 % | $ 6.3 M | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 4.41 | -2.22 % | $ 133 M | ||
|
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
-34 M | $ 9.56 | -3.82 % | $ 679 M | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
-70.9 M | $ 5.7 | -2.48 % | $ 233 M | ||
|
SCYNEXIS
SCYX
|
-31.1 M | $ 0.62 | 6.08 % | $ 29.7 M | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
14.4 M | $ 9.33 | -2.81 % | $ 5.77 B | ||
|
TherapeuticsMD
TXMD
|
3.68 M | $ 1.67 | -4.02 % | $ 17.4 M |